Would you re-test dulaglutide after two weeks at room temperature, or accept the original certificate?

What I have: dulaglutide · two weeks · room temperature.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

What would you do, and what would make you change course?

two weeks is 14 days, and at room temperature the ten-degree rule of thumb makes that roughly 47 refrigerated days of equivalent exposure. Room temperature is not a number, so take the pharmacopoeial 20–25 °C and its 22.5 °C midpoint: 17.5 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — puts that at about 3.4 times the refrigerated rate. It is an order-of-magnitude statement about a rate, not a shelf life, and the top of the 20–25 °C band runs about 1.4 times faster than the bottom of it. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 14 days will have moved one of them further than the other.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

What each test answers

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 2 Feb 2026 by thabo_maseko — added the citation requested in comments

It helps to be literal here: most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

Assume segregation is possible, and design your sampling to catch it if it exists.

In practice, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.